STAT+: Roche buys Telavant from Roivant for $7 billion, gaining bowel disease drug candidate
Roche said Monday it was buying Telavant Holdings for $7.1 billion upfront, picking up a promising experimental therapy for inflammatory bowel diseases.
Telavant is owned by Roivant Sciences, with Pfizer holding a minority stake. The deal will allow Roche to develop the therapy, called RVT-3101, and, pending approval, sell it in the United States and Japan. Pfizer holds the commercial rights in other parts of the world.
RVT-3101 has been tested in a Phase 2b trial in moderate to severe ulcerative colitis, showing improvements and remissions in some patients. Roche said it planned to start a Phase 3 trial.
Continue to STAT+ to read the full story…
